Predictors of duration of abiraterone acetate in men with castration resistant prostate cancer

BACKGROUND: Androgen receptor signaling remains important in castration resistant prostate cancer (CRPC) as demonstrated by the efficacy of abiraterone acetate (henceforth abiraterone) in phase III trials. Given that heterogeneous patient responses are observed, we sought to determine clinical facto...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate Cancer Prostatic Dis
Autors principals: McKay, Rana R., Werner, Lillian, Fiorillo, Matthew, Nakabayashi, Mari, Kantoff, Philip W., Taplin, Mary-Ellen
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034654/
https://ncbi.nlm.nih.gov/pubmed/27502737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2016.31
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars